Anti-PD1 Drug-resistant Tumor Models

Patient Derived Xenograft (PDX) Mouse Models and Efficacy Services
Leukemias PDXStomach Cancer PDXPancreatic Cancer PDXOvarian Cancer PDXLung cancer PDXColorectal Cancer PDXBreast Cancer PDXBladder Cancer PDX
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Anti-PD1 Drug-resistant Tumor ModelsIn Vivo Efficacy Studies Using TIGIT Humanized ModelsPDL1 Humanized Mouse ModelPD1 Humanized Mouse ModelsOX40 Humanized Mouse ModelsIn vivo Efficacy Test in LAG3 Humanized Mouse ModelsIn vivo Efficacy Test in GITR Humanized Mouse ModelCTLA4 Humanized Mouse ModelsIn vivo Efficacy Test in CD137 Humanized Models

The PD-1/PD-L1 axis is a well-known immune checkpoint, High activity within the PD-1/ PD-L1 axis promotes T cell dysfunction. Great progresses are made in recent years to use PD-1/PDL1 blockade therapy in cancer treatment. Studies have shown that primary resistance to anti-PD1 therapies is common, affecting up to 60% of patients in some cancer. Furthermore, it is now becoming apparent that initial responses observed among some patients can be undone by their development of acquired resistance to anti-PD1 therapies. Given the common problem, GemPharmatech has successfully developed a variety of anti-PD1 resistant model.

 

1.Keytruda-induced resistance model

Through inoculating anti-PD1 drug-sensitive tumor cell lines CT26 and MC38 on hPD1 target humanized mice, followed by induction with Keytruda, drug-resistant tumor strains were isolated and established. These resistant strains were then re-implanted into mice and subjected to drug treatment induction. After multiple cycles of this process, drug-resistant strains were eventually obtained.

图片1.png

图片2.png

Fig1. Keytruda-induced drug resistance model in CT26

图片3.png

图片4.png

Fig2. Keytruda-induced drug resistance model in MC38

 

2.MHC-I deficiency drug-resistant model

MHC-I (major histocompatibility complex class I), mainly mediates the process of endogenous antigen presentation, and knockout of B2M protein results in MHC-I deficiency.

图片5.png

Fig3. Keytruda efficacy test in subcutaneous tumor-bearing CT26 and CT26-mB2m KO models of BALB/c-hPD1 mice


3. Natural drug-resistant strain model

KPC: TIL analysis

图片6.png

Fig4. Subcutaneous inoculation of KPC cell line in C57BL/6J mice

 

Pan02: Drug efficacy data

图片7.png图片8.png

Fig5. Subcutaneous inoculation of Pan02 cell line in C57BL/6J mice

 

B16F10: Drug efficacy data and TIL analysis

图片9.png图片10.png

图片11.png

Fig6. Subcutaneous inoculation of B16F10 cell line in B6-hPD1/hLAG3 mice

 

LLC: TIL analysis

图片12.png

Fig7. Subcutaneous inoculation of LLC cell line in C57BL6-hPD1 mice

 

4T1: Drug efficacy data and TIL analysis

图片13.png

图片14.png

Fig8. Subcutaneous inoculation of 4T1 cell line in Balb/c-hPD1hTIGIT mice

 

EMT6: Drug efficacy data and TIL analysis 

图片15.png

图片16.png

Fig9. Subcutaneous inoculation of EMT6 cell line in BALB/c-hPDL1 mice

 

RENCA: Drug efficacy data and TIL analysis

图片17.png

图片18.png

Fig10. Subcutaneous inoculation of RENCA cell line in BALB/c-hPD1/hTIGIT mice

 

Characteristics and Application Scenarios of Various Drug Resistance Models

图片19.png


TALK WITH OUR EXPERTS

GemPharmatechは、お客様のプライバシーを保護し、尊重することをお約束します。お客様の個人情報は、アカウントの管理およびお客様からご要望いただいた製品やサービスの提供に利用いたします。時折、当社の製品やサービスに関する情報や、お客様に興味があるかもしれない他のコンテンツについてご連絡差し上げたいと考えております。お客様にこの目的をご連絡し、ご同意いただける場合は、以下の方法でお客様にどのようにご連絡させていただけるかをお知らせください。

ご希望のコンテンツを提供するために、お客様の個人データを保存および処理する必要があります。この目的でお客様の個人データを保存することにご同意いただける場合は、以下のチェックボックスをクリックしてください。

同意をいつでも撤回する権利があります。購読解除の詳細情報、当社のプライバシーに関する実践、およびお客様のプライバシーを保護し尊重するための取り組みについての詳細については、当社のプライバシーポリシーをご覧ください。